Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying Facebook has made too many enemies, including politicians, regulators, technology leaders, consumers, and employees, to not experience "long-term negative ramifications on its business." 2. Conatus (CNAT) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying the Encore-PH trial missed its pre-specified primary endpoint but post-hoc analyses demonstrated a trend towards statistically significant/emricasan-mediated improvements in patients with compensated cirrhosis and elevated baseline hepatic venous pressure gradient values. 3. BHP Billiton (BHP) downgraded to Neutral from Overweight at JPMorgan with analyst Lyndon Fagan saying the stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation." 4. Toll Brothers (TOL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Dahl citing a "sharper than expected weakness in orders and likelihood of further near-term declines," with softer margin assumptions attributed to a weaker outlook for orders. 5. Bluebird Bio (BLUE) downgraded to Neutral from Overweight at Piper Jaffray with analyst Tyler Van Buren saying the company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
